Abstract
Fluorescent glycolipids were utilized for detection of the intracellular, activator-dependent, activities of β-glucocerebrosidase and arylsulphatase A. Activities were measured in primary skin fibroblasts from normal individuals, from patients with Gaucher disease who had mutations within the β-glucocerebrosidase gene, and from a prosaposin-deficient patient. Fluorescent microscopy demonstrated that glucosylceramide or sulphatide labelled with a fluorescent probe (lissamine-rhodamine) were endocytosed and reached the lysosomes. There, in the presence of active enzyme and the corresponding saposin, they were hydrolysed to fluorescent ceramide, which changed its intracellular localization. When these substrates were labelled with pH-sensitive lissamine-rhodamine, which loses its fluorescence at neutral or alkaline pH, the transport of the product, i.e. fluorescent ceramide, from the lysosomes resulted in disappearance of the cellular fluorescence. In cells of patients having mutations within the genes encoding the glucocerebrosidase or the prosaposin, there was a considerable reduction in the intracellular rate of substrate hydrolysis that could be followed by fluorescence microscopy or measured quantitatively in cell extracts.
Similar content being viewed by others
References
Abrahamov A, Elstein D, Gross TV, et al (1995) Gaucher's disease variant characterized by progressive calcification of heart valves and unique genotype. Lancet 346: 1000–1003.
Agmon V, Monti E, Dagan A, Augusto P, Marchesini S, Gatt S (1993) Fluorescent-based diagnosis of lipid storage disease by analysis of the culture medium of skin fibroblasts. Clin Chim Acta 218: 139–147.
Agmon V, Khosravi R, Marchesini S, et al (1996) Intracellular degradation of sulforhodamine-GM1: use of a fluorescence-based characterization of GM2-gangliosidosis variants in fibroblasts and white blood cells. Clin Chim Acta 247: 105–120.
Beutler E, Gelbart T (1998) Hematologically important mutations: Gaucher disease. Blood Cells Mol Dis 24: 2–8.
Beutler E, Nguyen NJ, Henneberger MW, et al (1993) Gaucher disease: gene frequencies in the Ashkenazi Jewish population. Am J Hum Genet 52: 85–88.
Bradford MM (1976) A rapid sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 72: 248–254.
Brady RO, Barranger JA (1983) Glucosylceramide lipidosis: Gaucher disease. In Stanbury JB, Wyngaarden JB, Fredrickson DS, et al, eds. The Metabolic Basis of Inherited Disease. New York: McGraw-Hill, 842–856.
Brady RO, Kafner JN, Shapiro D (1965) Metabolism of glucocerebrosidase II. Evidence of an enzymatic deficiency in GaucherÏs disease. Biochem Biophys Res Commun 18 (2): 221–225.
Chatelut M, Leruth M, Harzer K, et al (1998) Natural ceramide is unable to escape the lysosome, in contrast to a Ñuorescent analogue. FEBS Lett 426: 102–106.
Eyal N, Wilder S, Horowitz M (1990) Prevalent and rare mutations among Gaucher patients. Gene 96: 277–283.
Gross-Tsur V, Har EY, Gutman I, Amir N (1989) Oculomotor apraxia: the presenting sign of Gaucher disease. Pediatr Neurol 5: 128–129.
Harzer K, Paton BC, Christomanou H, et al (1997) Saposins (sap) A and C activate the degradation of galactosylceramide in living cells. FEBS Lett 417: 270–274.
Ho MW, O'Brien JS (1971) Gaucher's disease: deÐciency of ‘acid’-glucosidase and reconstitution of enzyme activity in vitro. Proc Natl Acad Sci USA 68: 2810–2813.
Horowitz M, Pasmanik-Chor M, Borochowitz Z, et al (1998) Prevalence of glucocerebrosidase mutations in the Israeli Jewish population. Hum Mutat 12: 240–244.
Leonova T, Qi X, Bencosme A, Ponce E, Sun Y, Grabowski GA (1996) Proteolytic processing patterns of prosaposin in insect and mammalian cells. J Biol Chem 271: 17312–17320.
Lipsky NG, Pagano RE (1983) Sphingolipid metabolism in cultured fibroblasts: microscopic and biochemical studies employing a Ñuorescent ceramide analogue. Proc Natl Acad Sci USA 80: 2608–2612.
Lipsky NG, Pagano RE (1995) Intracellular translocation of fluorescent sphingolipids in cultured Ðbroblasts: endogenously synthesized sphingolipids and glucocerebroside analogues pass through the Golgi apparatus en route to the plasma membrane. J Cell Biol 100: 27–34.
Marchesini S, Gatt S, Agmon V, Giudici ML, Monti E (1992) A novel Ñuorescent pH indicator for the acidic range. Biochem Int 27: 545–550.
Mehl E, Jatzkewitz H (1964) [A cerebrosidesulfatase from swine kidney]. Hoppe Seylers Z Physiol Chem 339: 260–276.
O'Brien JS, Kishimoto Y (1991) Saposin proteins: structure, function, and role in human lysosomal storage disorders. FASEB J 5: 301–308.
O'Brien JS, Carson GS, Seo HC, et al (1995) Identification of the neurotrophic factor sequence of prosaposin. FASEB J 9: 681–685.
Pasmanik-Chor M, Laadan S, Elroy-Stein O, et al (1996) The glucocerebrosidase D409H mutation in Gaucher disease. Biochem Mol Med 59: 125–133.
Paton BC, Schmid B, Kustermann KB, Poulos A, Harzer K (1992) Additional biochemical findings in a patient and fetal sibling with a genetic defect in the sphingolipid activator protein (SAP) precursor, prosaposin. Evidence for a deficiency in SAP-1 and for a normal lysosomal neuraminidase. Biochem J 285: 481–488.
Reiner O, Horowitz M (1988) Differential expression of the human glucocerebrosidase-coding gene. Gene 73: 469–478.
Sandhoff K, Harzer K, Furst W (1995) Sphingolipid activator proteins. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 7th edn. New York: McGraw-Hill, 2427–2441.
Schnabel D, Schroder M, Furst M, et al (1992) Simultaneous deficiency of sphingolipid activator proteins 1 and 2 is caused by a mutation in the initiation codon of their common gene. J Biol Chem 267: 3312–3315.
Tsuji S, Choudary PV, Martin BM, et al (1987) A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher's disease. N Engl J Med 316: 570–575.
Tsuji S, Martin BM, Barranger JA, Stubblefield BK, LaMarca ME, Ginns EI (1988) Genetic heterogeneity in type 1 Gaucher disease: multiple genotypes in Ashkenazic and non-Ashkenazic individuals. Proc Natl Acad Sci USA 85: 2349–2352.
Zimran A, Gelbart T, Westwood B, Grabowski GA, Beutler E (1991) High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews. Am J Hum Genet 49: 855–859.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Madar-Shapiro, L., Pasmanik-Chor, M., Dinur, T. et al. Intracellular degradation of fluorescent glycolipids by lysosomal enzymes and their activators. J Inherit Metab Dis 22, 623–637 (1999). https://doi.org/10.1023/A:1005573812430
Issue Date:
DOI: https://doi.org/10.1023/A:1005573812430